Researchers Discover Antibody that Blocks SARS-CoV-2 Infection in CellsMay 6, 2020
A team of researchers from The Netherlands has identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells. Researchers from Utrecht University, Erasmus Medical Center, and Harbour BioMed (HBM) reported the discovery, an initial step towards developing a fully human antibody to treat or prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.
Associate Professor Berend-Jan Bosch, research leader at Utrecht University, and co-lead author of the Nature Communications study said that their current research is built on the work done in the past on antibodies targeting the SARS-CoV that emerged in 2002/2003. From this collection of antibodies, their team identified an antibody that also neutralizes infection of SARS-CoV-2 in cultured cells. Bosch notes that the antibody binds to a domain that is conserved in both SARS-CoV and SARS-CoV-2. "This cross-neutralizing feature of the antibody suggests it may have potential in mitigation of diseases caused by future-emerging related coronaviruses," he added.
Generated using Harbour BioMed's H2L2 transgenic mouse technology, the discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment, said Frank Grosveld, co-lead author on the study, professor of cell biology at Erasmus Medical Center, and Founding Chief Scientific Officer at Harbour BioMed. He added that the antibody used in their work is "fully human," allowing development to proceed more rapidly and reducing the potential for immune-related side effects.
For more details, read the news article at the Utrecht University website.
You might also like:
- Scientists Say COVID-19 Coronavirus Has Natural Origins
- Nanoengineers Combine Molecular Farming and Advanced Manufacturing to Develop COVID-19 Vaccine
- Researchers in Spain Use Biotech to Produce SARS-CoV-2 Vaccine in Plants
The Crop Biotech Update is a weekly newsletter of ISAAA, a not-for-profit organization. The CBU is distributed for free to over 23,000 subscribers worldwide to inform them about the key developments in biosciences, especially in agricultural biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
- Researchers Discover Antibody that Blocks SARS-CoV-2 Infection in Cells
- The Role of Plant Biotechnology Against SARS-CoV-2
- Canadian Researchers Use Algae to Produce COVID-19 Test Kits
- Food Security Expert Says COVID-19 Pandemic Calls for Reassessment of Food Systems
News from Around the World
- U.S. EPA Grants Approval to Conduct GE Mosquito Field Trials
- Experts Discover Rice Proteins Vital for Pollination
- Scientists a Step Closer to Heat-tolerant Wheat
- Next-generation Sequencing of Poplar Lines Confirms Vector-free Transformation
- CRT1a Knockout Reduces Plant Susceptibility to Fungal Attack
Plant Breeding Innovations
- CRISPR-Cas9 Technology Reveals Function of OsRhoGDI2
Read the latest:
- Crop Biotech Update (August 17, 2022)
- Genome Editing Supplement (August 10, 2022)
- Gene Drive Supplement (July 27, 2022)
Subscribe to CBU: